Therapeutic Response

PD-L1 (CPS) >= 1 status confers therapeutic sensitivity to Pembrolizumab in patients with Cervical Adenocarcinoma.

Statements

Source and description
Keytruda (pembrolizumab) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to pembrolizumab for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS >=1), as determined by an FDA-approved test.
Pembrolizumab 200mg Monotherapy. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab (200mg and 400mg) for reimbursement as a monotherapy treatment option for the maintenance treatment of adult patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 with a CPS >= 1 who have completed the induction chemotherapy component of treatment.
Pembrolizumab 400mg Monotherapy. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab (200mg and 400mg) for reimbursement as a monotherapy treatment option for the maintenance treatment of adult patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 with a CPS >= 1 who have completed the induction chemotherapy component of treatment.